Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Amortizatization of Intangibles for 7 consecutive years, with $176000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Amortizatization of Intangibles rose 37.5% year-over-year to $176000.0; the trailing twelve-month figure through Jun 2026 stood at $630000.0 (up 23.29% YoY), and the FY2025 full-year result was $537000.0, down 28.11% from the prior year.
• Amortizatization of Intangibles climbed to $176000.0 in Q2 2026 per XERS's latest filing, from $163000.0 in the prior quarter.
• Across five years, Amortizatization of Intangibles topped out at $574000.0 in Q4 2022 and bottomed at -$79000.0 in Q2 2022.
• Historically, Amortizatization of Intangibles has averaged $184000.0 across 5 years, with a median of $157000.0 in 2025.
• The widest YoY moves for Amortizatization of Intangibles: up 1705.26% in 2023, down 74.56% in 2023.
• Over 5 years, Amortizatization of Intangibles stood at $574000.0 in 2022, then sank by 74.56% to $146000.0 in 2023, then plunged by 50.0% to $73000.0 in 2024, then surged by 106.85% to $151000.0 in 2025, then climbed by 16.56% to $176000.0 in 2026.
• According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $176000.0, $163000.0, and $151000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.